Collegium Pharmaceutical is transforming from a pain-management company to a central nervous system (CNS) platform by acquiring AZSTARYS, an ADHD drug franchise. The $650 million acquisition, funded by cash and debt, is projected to generate $60–70 million in revenue by 2026 and create over $50 million in annual synergies within a year. The company forecasts 2026 revenue between $865 million and $895 million with a strong adjusted EBITDA margin of 55%, reflecting early benefits from AZSTARYS. Despite this growth potential and immediate earnings boost, the market undervalues Collegium, trading at a low EV/EBITDA multiple of 3.47x.
Trust Carbon Infrastructure unveiled its HXS compute-efficiency layer, which reduces energy consumption by up to 50.5% and increases server throughput by 167% on NVIDIA H100 GPUs without changing AI model outputs. Tested on models from Alibaba, Meta,...
Nomura Real Estate Holdings reported a decrease in Q1 operating revenue to JPY 191 billion and net profit to JPY 14.7 billion compared to last year, mainly due to fewer housing units sold and lower property sales. Despite this, progress on housing an...
The Schwab International Equity ETF (SCHF) tracks the FTSE Developed ex US Index, providing investors with broad exposure to developed international markets, notably Japan. The ETF benefits from strong Japanese wage growth, moderate inflation, and co...
The Vanguard Extended Duration Treasury ETF (EDV) currently offers a 5.38% SEC yield with a low expense ratio of 0.05%. However, it carries significant duration risk, meaning a small increase in long-term Treasury yields can wipe out a year's income....
Fox Tungsten Ltd has begun a fully funded 20,000-metre drill program at its Fox Project in British Columbia, targeting the world's highest grade tungsten asset. Early visual observations show consistent presence of scheelite, the tungsten-bearing min...
